Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00 2022-12-09 pm EST
40.65 USD   -1.36%
11/29Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th Annual Healthcare Conference, Nov-29-2022 10:00 AM
CI
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ultragenyx to Participate at Citi BioPharma Conference

09/01/2022 | 04:01pm EST

NOVATO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Eric Crombez, Chief Medical Officer, Gene Therapy, will participate in a Rare Disease Panel at Citi's 17th Annual BioPharma Conference on Wednesday, September 7, 2022, at 11:20 AM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts
Ultragenyx Pharmaceutical, Inc.
Investors  
Joshua Higa 
ir@ultragenyx.com  

Media  
Jeff Blake 
415-612-7784 
media@ultragenyx.com


Primary Logo

Source: Ultragenyx Pharmaceutical Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about ULTRAGENYX PHARMACEUTICAL INC.
11/29Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th An..
CI
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/21Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
11/18Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
11/18Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/17Transcript : Ultragenyx Pharmaceutical Inc. Presents at 13th Annual Jefferies..
CI
11/15Transcript : Ultragenyx Pharmaceutical Inc. Presents at Stifel 2022 Healthcar..
CI
11/11Ultragenyx Pharmaceutical Chief Financial Officer Mardi Dier to Depart for Private Biop..
MT
11/10Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2022 365 M - -
Net income 2022 -684 M - -
Net cash 2022 760 M - -
P/E ratio 2022 -4,16x
Yield 2022 -
Capitalization 2 850 M 2 850 M -
EV / Sales 2022 5,72x
EV / Sales 2023 5,50x
Nbr of Employees 1 119
Free-Float 95,1%
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 40,65 $
Average target price 97,00 $
Spread / Average Target 139%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Samuel C. Wadsworth Chief Scientific Office
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-50.99%2 889
VERTEX PHARMACEUTICALS46.32%82 480
REGENERON PHARMACEUTICALS, INC.18.77%81 748
BIONTECH SE-33.36%41 753
WUXI APPTEC CO., LTD.-32.53%33 492
GENMAB A/S23.08%29 964